Q4 2025 Medicure Inc Earnings Call Transcript
Key Points
- Medicure Inc (MCUJF) reported a significant increase in net revenue for the year ending December 31, 2025, reaching $28.9 million compared to $21.9 million in the previous year.
- The company's investment of $3.2 million in R&D highlights its commitment to advancing innovative therapies, particularly the Phase 3 trial of MC-1 for PNPO deficiency.
- Revenue from Marley Drug increased to $12.8 million, up from $10.8 million in the previous year, driven by higher sales of ZYPITAMAG and other exclusive products.
- The acquisition of Gateway Medical Pharmacy and West Olympia Pharmacy has created additional synergies and channels for marketing and selling ZYPITAMAG.
- Medicure Inc (MCUJF) has received fast-track designation for its MC-1 therapy, which could lead to a priority review voucher and significant value if successful.
- The company recorded a net loss of $7.1 million for the year ending December 31, 2025, compared to a net loss of $1 million in the previous year.
- Net revenue from AGGRASTAT decreased to $5.7 million from $8.1 million due to increased competition from generic alternatives.
- A CMS rebate liability of $2.1 million negatively impacted the company's financials, and the company is appealing the assessment.
- The decrease in net revenue from ZYPITAMAG through traditional insurance channels is attributed to lower utilization, particularly in Medicare Part D.
- Adjusted EBITDA for the year was negative $1.5 million, a decline from the previous year's negative $437,000, primarily due to lower net revenue from AGGRASTAT and higher costs in the pharmacy segment.
Good day, and welcome to Medicure's earnings conference call for the year ended December 2025. My name is Ali, and I will be your operator for today's call. (Operator Instructions)
Before we proceed, I would like to remind everyone that this presentation contains forward-looking statements relating to future results, events, and expectations which are pursuant to the Safe Harbor provisions of the United States Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, those described in the company's most recent annual information form and Form 20-F.
Later, we will conduct a question-and-answer session. And please note this conference call is being recorded, and today's date is April 27, 2026.
I would now like to turn the conference call over to Dr. Albert Friesen, Chief Executive Officer of Medicure, Inc. Please go ahead, Dr. Friesen.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
